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Abstract
Background: Circulating tumor cells (CTCs) play a crucial role in tumor dissemination and are an independent
survival predictor in breast cancer (BC) patients. Epithelial to mesenchymal transition (EMT) is involved in cancer
invasion and metastasis. The aim of this study was to assess correlation between CTCs and expression of EMT
transcription factors TWIST1 and SLUG in breast tumor tissue.
Methods: This study included 102 early BC patients treated by primary surgery. Peripheral blood mononuclear
cells (PBMC) were depleted of hematopoietic cells using RossetteSep™ negative selection kit. RNA extracted from
CD45-depleted PBMC was interrogated for expression of EMT (TWIST1, SNAIL1, SLUG, FOXC2 and ZEB1) and
epithelial (KRT19) gene transcripts by qRT-PCR. Expression of TWIST1 and SLUG in surgical specimens was evaluated
by immunohistochemistry and quantified by multiplicative score.
Results: CTCs were detected in 24.5 % patients. CTCs exhibiting only epithelial markers were present in 8.8 %
patients, whereas CTCs with only EMT markers were observed in 12.8 % of pts and CTCs co-expressing both
markers were detected in 2.9 % pts. We observed lack of correlation between CTCs and expression of TWIST1
and SLUG in breast cancer cells or cancer associated stroma. Lack of correlation was observed for epithelial CTCs as
well as for CTCs with EMT.
Conclusions: In this translational study, we showed a lack of association between CTCs and expression of
EMT-inducing transcription factors, TWIST1 and SLUG, in breast tumor tissue. Despite the fact that EMT is involved
in cancer invasion and metastasis our results suggest, that expression of EMT proteins in unselected tumor tissue is
not surrogate marker of CTCs with either mesenchymal or epithelial features.
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Background
Circulating tumor cells (CTCs) have a crucial role in the
metastatic cascade, tumor dissemination and pro-
gression. Prognostic value of CTCs was demonstrated by
numerous trials for metastatic as well as primary breast
cancer [1–4]. However, CTCs represent a heterogeneous
population of cells with different phenotypes and bio-
logical value [5].
To successfully execute the metastatic cascade, epithe-
lial tumor cells must detach from the primary tumor,
pass through the peripheral circulation, extravasate at
the distant site and establish a new tumor. Increased
number of studies demonstrated that cancer cells often
undergo epithelial to mesenchymal transition (EMT), to
acquire the traits needed to execute the multiple steps of
metastasis [6]. During the EMT, epithelial cells downreg-
ulate epithelial-related genes, acquire mesenchymal gene
expression and undergo major changes in their cytoskel-
eton that result in loss of cell–cell contacts and cell
polarity leading to increased motility and invasiveness
[7]. EMT is associated with de novo expression of stem
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cell markers and acquisition of functional stem cell
properties [8]. Several signaling pathways are involved in
the induction of EMT including TGF-β1, Wnt, Notch or
Hedgehog signaling. Overexpression of transcription
factors (TF), including TWIST1, SNAIL1, SLUG, ZEB1
and/or FOXC1,2, can induce EMT in mammary epithe-
lial cells and/or breast cancer cells as well [9, 10].
Several studies evaluated expression of EMT transcrip-
tion factors (SNAIL, SLUG, ZEB1, ZEB2, TWIST1, and
TWIST2) in breast cancer tissue sections [11–14]. Studies
showed that the level of SNAIL and TWIST expression
was associated with a worse patient outcome [15–17].
Moreover, some types of breast cancer including basal
like, claudin low and metaplastic carcinoma show upre-
gulation of mesenchymal markers and reduced levels of
epithelial markers, consistent with EMT [18–20].
Experimental and clinical data suggest that the EMT
has an important role in the generation of CTCs and the
acquisition of resistance to therapy. Inhibition of TWIST
in the highly metastatic 4 T1 murine mammary cell line
reduced both metastatic burden and the number of
CTCs in mice bearing xenograft mammary tumors, thus
linking EMT, metastasis and the presence of CTCs [10].
Experimental and translational research data suggest
that there is a continuum of development of CTCs that
range from one end of the spectrum (epithelial pheno-
type) to the other end of the spectrum (mesenchymal
phenotype) and include those with a partial EMT
phenotype [5, 21–23]. Recently, it was showed that
CTCs exhibit dynamic changes in epithelial and mesen-
chymal composition [21].
In this translational study, we hypothesized, that acti-
vation of EMT in primary tumor could be involved in
CTCs release into peripheral blood (PB) and therefore
CTCs will be detected more often in breast cancer
patients with high expression of EMT-induced TFs in
primary tumor or tumor associated stroma. Therefore,
we examined expression of EMT induced TFs on breast
tumor tissue as well as tumor associated stroma and cor-
related them with CTCs in peripheral blood. We
elected to study the early breast cancer model, to avoid




As a part of ongoing translational study (Protocol TRU-
SK 002; Chair: M. Mego), 102 patients with stages I–III
primary breast cancer (PBC) who were undergoing defini-
tive surgery were included. From each patient we obtained
peripheral blood for CTCs detection and corresponding
paraffin-embedded tumor tissue. The blood was drawn in
the morning on the day of surgery, before surgical pro-
cedure. Each patient was given a complete diagnostic
evaluation to exclude the presence of distant metastasis.
Patients with concurrent malignancy other than non-
melanoma skin cancer in the previous 5 years were
excluded as well. In all patients, data regarding age,
tumor stage, histology, regional lymph node involve-
ment, hormone receptor status, and HER2 status were
also recorded.
The study was approved by the Institutional Review
Board (IRB) of the National Cancer Institute of Slovakia
and was conducted between March and December 2012
and each participant signed informed consent before
study enrollment. Healthy donors (N = 60) were age-
matched women without breast cancer who were re-
cruited and consented according to the IRB-approved
protocol. Each participant signed informed consent.
Detection of CTC in peripheral blood
CTC were detected in peripheral blood by quantitative
real-time polymerase chain reaction (qRT-PCR) based
assay utilizing CD45 positive (CD45+) cells depletion for
CTCs enrichment, as described previously [24, 25].
RNA extraction and cell lines
Peripheral blood was subjected to CD45 depletion using
RossetteSep™ kit (StemCell technologies) according to
the manufacturer’s instructions. CD45-depleted cells were
mixed with 500 μl of TRIzol® LS Reagent (Invitrogen
Corporation, Carlsbad, CA) and stored at −80 °C until it
was necessary to extract RNA according to the manufac-
turer’s instructions. The precipitated pellet containing
RNA was dissolved in 50 μl of nuclease-free water. All
RNA preparation and handling steps took place in a lam-
inar flow hood, under RNase-free conditions. RNA con-
centration was determined by absorbance readings at
260 nm (median = 5.95 ng/μl, range: 1.7 – 38.3). RNA ex-
tracted from HeLa, HCT 116, MCF7 and MDA-MB-231
cells were used as positive controls.
Identification of gene transcripts in CD45-depleted subsets
Isolated RNA was subjected to quantitative RT-PCR
(qRT-PCR) to detect EMT-inducing TF gene transcripts
(TWIST, SNAIL1, SLUG, ZEB1 and FOXC2) and epithe-
lial antigen (KRT19). In brief, 2.5 μL of RNA were placed
in 25 μL of reaction volume containing 12.5 μL of Quanti-
Fast Probe RT-PCR Kit Master Mix, 0.25 μL QuantiFast
RT Mix, 8.5 μL water and 1.25 μL of primers. The follow-
ing TaqMan assays were purchased from LifeTechnologies
(USA): TWIST1: Hs00361186_m1; SNAIL1: Hs0019
5591_m1; SLUG: Hs00161904_m1; ZEB1: Hs01566408_
m1; FOXC2: Hs01013460_s1; GAPDH: Hs99999905_m1;
KRT19 Hs00761767_s1. Amplicons or probes spanned in-
tron–exon boundaries, with the exception of FOXC2 and
KRT19. Amplification was performed on an Eppendorf
Realplex Real-Time PCR system (Eppendorf, Germany)
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using the cycling program: 95 °C for 10 min; 40 cycles of
95 °C for 15 s and 60 °C for 60 s. All samples were
analyzed in triplicate. Calibrator samples were run with
every plate to ensure consistency of the PCR. For all
fluorescence-based RT-PCR, fluorescence was detected
between 0 and 40 cycles for the control and marker genes
in single-plex reactions, which allowed for the deduction
of the cycles at threshold (Ct) value for each product.
Expression of the genes of interest was calibrated against
expression of the housekeeping gene, GAPDH. Target
cDNA was quantified using the delta-Ct method with the
formula: 1 = 2 Ct(target-GAPDH).
CTC definition
Patient samples with higher KRT19 gene transcripts
than those of healthy donors were scored as epithelial
CTCs positive (CTC_EP), while patient samples with
higher EMT-TF (TWIST1, SNAIL1, SLUG, ZEB1 and
FOXC2) gene transcripts than those of healthy donors
were scored as CTC_EMT positive. Expression of at
least one of the markers (either epithelial or mesenchy-
mal) at levels above the defined cutoff was sufficient to
define a sample as CTC positive.
The highest expression levels of the KRT19 and EMT-
inducing TF gene transcripts relative to that of GAPDH
were 3.4 × 10 −3 (median 2.8 ×10−6, range: 0–3.4 × 10−3)
for KRT19, 7.5 × 10−4 (median 0, range: 0–7.5 × 10−4) for
TWIST1, 3.8 × 10−2 (median 0.003135, range: 5.0 × 10−4 -
3.8 × 10−2) for SNAIL1, 1.7 × 10−1 (median 1.4 × 10−2,
range: 2.2 × 10−3 – 1.7 × 10−1) for ZEB1 and 4.0 × 10−2
(median 4.0 × 10−3, range: 1.7 × 10−4 – 4.0 × 10−2) for
FOXC2, while SLUG transcripts were not detected in any
of the samples from healthy donor. These highest ex-
pression values in healthy donors were used as “cutoff” to
determine CTCs positivity.
Tumor pathology
Pathology review was conducted at the Department of
Pathology, Faculty of Medicine, Comenius University, by
two pathologists (ZC and PJ) associated with the study.
Diagnosis and tumor samples
The study included tumor specimens from 102 patients.
All specimens were classified according to the WHO
Classification of 2004. The block containing the most
representative part of the tumor was identified by H&E
microscopy and used for IHC analysis.
Tissue microarray construction
According to tumor histology, one or two representative
tumor areas were identified on H&E sections. Sections
were matched to their corresponding wax blocks (the
donor blocks), and 3-mm diameter cores of the tumor
were removed from these donor blocks with the
multipurpose sampling tool Harris Uni-Core (Sigma-
Aldrich, Steinheim, Germany) and inserted into the
recipient master block. The recipient block was cut
into 5-μm sections, and the sections were transferred
to coated slides.
Immunohistochemical (IHC) staining
Slides were deparaffinised and rehydrated in phosphate
buffered saline solution (10 mM, pH 7.2). The tissue
epitopes were demasked using the automated water
bath heating process in Dako PT Link (Dako,
Glostrup, Denmark); the slides were incubated in
TRIS-EDTA retrieval solution (10 mM TRIS, 1 mM
EDTA pH 9.0) at 98 °C for 40 min (TWIST1 stain-
ing) or for 20 min (SLUG staining). The slides were
subsequently incubated overnight at room tempe-
rature with the primary mouse monoclonal antibody
against TWIST1 (Abcam, Twist2C1a, ab50887) diluted
1:100; or overnight at 4 °C with the primary mouse
monoclonal antibody against SLUG (Santa Cruz, A-7,
sc-166476) diluted 1:50 in Dako REAL antibody dilu-
ent (Dako, Glostrup, Denmark) and immunostained
using rabbit anti-mouse immuno-peroxidase polymer
(EnVision FLEX/HRP, Dako, Glostrup, Denmark) for
30 min at room temperature, according to the manu-
facturer’s instructions. For visualisation, the diamino-
benzidine substrate-chromogen solution was used
(DAB, Dako, Glostrup, Denmark) for 5 min. Finally,
the slides were counterstained with haematoxylin. As
tumour associated stroma, the stromal cells between
tumour nests, adjacent to tumour cells were evaluated.
Cancer associated stroma was indicated by vimentin-posi-
tive (Dako, Monoclonal mouse anti-vimentin clone
V9, code IR630) and pan-cytokeratin-negative (Dako,
Monoclonal mouse anti-human clones AE1/AE3, code
M3515). Samples of breast carcinoma with high ex-
pression of TWIST1 served as the positive control
TWIST1 as described previously [26] and placental
tissue served as a positive control for SLUG. As nega-
tive control, breast tissue was subjected to the same
procedure without staining with the primary antibody.
Immunohistochemical stain scoring
Tumor cores were independently assessed by two patholo-
gists (ZC and PJ) who were blinded to clinico-pathological
data. In cases of disagreement, the result was reached by
consensus. The result of the IHC analyses was expressed
by a weighted histoscore, evaluating both the percentage
of positive cells (PP) and the staining intensity (SI) of
the nuclei. Briefly, the proportion of cells with nu-
clear staining was multiplied by the intensity of stain-
ing to provide a score ranging from 0–300. The score
was calculated as follows: Score = (0 × percentage not
stained) + (1 × percentage weakly stained) + (2 ×
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percentage moderately stained) + (3 × percentage
strongly stained) [15].
Statistical analysis
Patient characteristics were tabulated. The patients’ char-
acteristics were summarized using the median (range)
for continuous variables and frequency (percentage) for
categorical variables. Normality of distribution was
tested by the Kolmogorov-Smirnoff test. If normally dis-
tributed, sample means were tested by Student t-test or
analysis of variance (ANOVA) with Bonferroni’s or
Tamhane’s corrections, depending on homogeneity of
variance. Nonparametric Mann–Whitney U or Kruskal-
Wallis H test were used for non-normally distributed data.
Pearson’s or Spearman’s correlations were used according
to the normality of data. All p values presented are two-
sided, and associations were considered significant if
the p value is less or equal to 0.05. Statistical analyses
were performed using NCSS 2007 software (Hintze J,
2007, Kaysville, Utah, USA).
Results
The study population consisted of 102 primary breast
cancer patients with median age of 60 years (range: 37–
83 years). Patients’ characteristics are shown in Table 1.
There were 86 (84.3 %) patients with estrogen receptor
positive (ER) and/or progesterone receptor positive (PR)
tumors; 16 (15.7 %) patients with HER-2/neu amplified
tumors.
CTC detection
To determine overexpression of the EMT-inducing TF
gene transcripts and KRT19 in PBC patients, we com-
pared the expression levels in patient samples with those
of HDs. Totally, CTCs were detected in 25 (24.5 %) of
patients. CTCs with only epithelial markers were present
in peripheral blood of 9 (8.8 %) patients; CTC with EMT
only phenotype were present in 13 (12.8 %) of patients;
in 3 (2.9 %) of patients CTCs exhibited both epithelial
and mesenchymal markers (Table 2). In one patient sam-
ple, there was overexpression of two EMT-inducing TF
gene transcripts (SLUG and TWIST1), e.g., expression
of both genes were higher than the cut-off value in the
same sample.










1 and 2 60 58.8
3 40 39.2
Histology
Invasive ductal carcinoma 85 83.3
Other 17 16.7
Hormone receptor status
Negative for both 16 15.7
















Table 2 CTC detection and expression of the genes in CD45
depleted peripheral blood at levels higher than those of healthy
donors







CTC_EP only 9 8.8




Any CTC 25 24.5
aIn one patient sample, there was overexpression of two EMT-inducing TF
gene transcripts (SLUG and TWIST1)
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Fig. 1 TWIST1 expression in primary breast tumours. Immunohistochemical reaction with anti-TWIST1 monoclonal antibody. Original magnification × 400
visualisation with 3,3’-diaminobenzidine . a staining intensity 0, b staining intensity 1, c staining intensity 2. There were no tumours with staining
intensity 3
Fig. 2 SLUG expression in primary breast tumours. Immunohistochemical reaction with anti SLUG monoclonal antibody. Original magnification ×
400 visualisation with 3,3’-diaminobenzidine. a staining intensity 0, b staining intensity 1, c staining intensity 2, d staining intensity 3
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CTCs and EMT- inducing transcription factors in breast
cancer cells and tumor associated stroma
Tumor expression of TWIST1 and SLUG are associated
with poor outcome in breast cancer patients; therefore,
we decided to correlate presence of CTCs in peripheral
blood with expression of TWIST1 and SLUG in breast
cancer cells and cancer associated stroma (Figs. 1 and 2).
Expression of TWIST1 and SLUG were detected in 42
(41.7 %) and 76 (74.5 %) of samples, respectively.
Mean ± SEM (standard error of mean) for TWIST1
and SLUG expression in breast cancer cells and tumor
associated stroma was 8.6 ± 2.2 vs. 54.4 ± 5.1, p < 0.0001,
and 40.6 ± 4.2 vs. 37.3 ± 2.8, p = 0.12, respectively. We
observed correlation between TWIST1 and SLUG expres-
sion in tumor stroma (Spearman rho’ = 0.37; p = 0.0003).
Expression of TWIST1 and SLUG in relation to CTCs
and various clinicopathological characteristics is shown in
Tables 3 and 4.
We observed a lack of association between CTCs and
expression of TWIST1 and SLUG in breast cancer cells
or cancer associated stroma. Lack of correlation was
consistent for epithelial CTCs as well as for CTC_EMT
Table 3 TWIST1 expression in tumor cells and tumor stroma
Variable TWIST1 expression in breast tumor cellsa TWIST1 expression in tumor stromaa
N Mean SEM p-valueb Mean SEM p-valueb
All 102 8.6 2.2 NA 40.6 4.2 NA
T-stage
1 64 7.7 2.8 0.05 48.7 5.1 0.0007
>1 38 10.1 3.6 26.0 6.8
N-stage
0 60 9.5 2.9 0.87 44.3 5.4 0.09
>1 42 7.3 3.4 35.0 6.6
Grade
1 and 2 60 10.2 2.9 0.35 38.7 5.6 0.86
3 40 6.6 3.5 43.6 6.7
Histology
IDC 85 9.0 2.4 0.25 44.2 4.5 0.06
Other 17 6.8 5.4 22.5 10.1
Hormone receptor status
Negative 16 1.8 5.9 0.23 36.8 11.0 0.53
Positive 86 9.7 2.4 41.2 4.6
HER2 status
Positive 16 17.8 5.4 0.74 42.5 10.3 0.75
Negative 86 6.8 2.4 40.2 4.6
Ki 67 (cut-off 14 %)
Low 51 9.1 3.1 0.83 39.0 5.9 0.60
High 51 8.1 3.2 42.2 6.0
Epithelial CTC
Present 12 4.2 6.4 0.96 43.3 11.9 0.75
Absent 90 9.2 2.4 40.2 4.5
EMT CTC
Present 16 7.8 5.5 0.62 42.2 10.3 0.98
Absent 86 8.7 2.4 40.3 4.6
Any CTC
Present 25 6.2 4.4 0.71 44.6 8.2 0.68
Absent 77 9.4 2.6 39.1 4.9
aProtein expression evaluated semi quantitatively by immunohistochemistry
bNonparametric Mann–Whitney U test
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(Table 5). Moreover, there was a trend for decreased
expression of SLUG in tumor associated stroma in pa-
tients positive for CTCs_EMT (mean ± SEM: 24.3 ± 7.5
vs. 39.4 ± 3.0, p = 0.06).
TWIST1 expression was increased in breast cancer
cells and decreased in tumor associated stroma in patients
with > T1 tumors, while SLUG expression was increased
in cancer cells of tumors with low and intermediate grade
and in tumors with decreased proliferation (low Ki67).
There was no association between expression of TWIST1
and SLUG and ER/PR status, HER2/neu amplification or
axillary lymph node status (Tables 3 and 4).
Discussion
In this translational study, we showed lack of association
between CTCs and expression of EMT-inducing tran-
scription factors, TWIST1 and SLUG, in primary breast
tumor tissue. Moreover, this observation was consistent
for both epithelial CTCs and CTCs with EMT pheno-
type, as well as for TWIST1 and SLUG expression in
breast cancer cells and cancer associated stroma.
Several translational studies demonstrated activation
of EMT in a subpopulation of CTCs including expres-
sion of EMT inducing TFs on CTCs [21–23]. However,
in our study there was no correlation even between
Table 4 SLUG expression in tumor cells and tumor stroma
Variable SLUG expression in breast tumor cellsa SLUG expression in tumor stromaa
N Mean SEM p-value b Mean SEM p-value b
All 102 54.4 5.1 NA 37.3 2.8 NA
T-stage
1 64 56.7 6.5 0.42 41.3 3.5 0.08
>1 38 50.5 8.3 30.8 4.5
N-stage
0 60 61.3 6.6 0.10 38.0 3.7 0.67
>1 42 44.4 7.9 36.3 4.4
Grade
1 and 2 60 62.3 6.4 0.007 38.6 3.7 0.58
3 40 39.5 7.7 35.0 4.5
Histology
IDC 85 51.3 5.5 0.18 38.9 3.1 0.28
Other 17 70.6 12.7 28.8 7.0
Hormone receptor status
Negative 16 53.8 12.8 0.78 31.9 7.1 0.32
Positive 86 54.5 5.6 38.4 3.1
HER2 status
Negative 16 45.3 12.8 0.29 39.4 7.1 0.46
Positive 86 56.1 5.6 36.9 3.1
Ki 67 (cut-off 14 %)
Low 51 68.2 6.9 0.002 32.9 3.9 0.09
High 51 39.9 7.0 41.8 4.0
Epithelial CTC
Present 12 55.8 14.8 0.81 45.8 8.1 0.41
Absent 90 54.2 5.5 36.2 3.0
EMT CTC
Present 16 52.5 12.8 0.97 31.3 7.1 0.29
Absent 86 54.7 5.6 38.5 3.1
Any CTC
Present 25 55.2 10.2 0.78 37.2 5.7 0.88
Absent 77 54.1 5.9 37.4 3.3
aProtein expression evaluated semi quantitatively by immunohistochemistry
bNonparametric Mann–Whitney U test
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CTCs_EMT and expression of EMT TFs in tumor tissue.
Demonstration of EMT in tissues is limited by the
nature of the EMT process: its transient, dynamic, and
reversible characteristics [17]. Moreover, there is great
variability in evaluating expression of EMT factors be-
tween studies. In a study by van Ness et al., high expres-
sion of TWIST1 and SNAIL1 was observed in 50 % and
54 % of patients while Soini et al., detected TWIST1 and
SNAIL1 expression in 3.6 % and 3.1 % respectively [15,
17]. In our study we detected expression of TWIST1 in
41 % of samples. We evaluated expression of TWIST1
and SLUG in tumor tissue, but not other EMT inducing
TFs, therefore, we cannot exclude, that expression of
other EMT TFs could be associated with presence of
CTCs in peripheral blood. We observed higher SLUG
expression in clinically less aggressive tumors (lower
grade, lower proliferation) and higher TWIST1 expres-
sion was associated with higher tumor stage. These data
are consistent with previous observations [15].
We revealed higher expression of TWIST1 in stromal
compartment compared to epithelial cells, while there
was no difference in SLUG expression between these
two compartments. Expression of EMT-inducing TFs in
the stromal compartment of breast carcinomas possibly
represents two populations of cells; EMT transformed
neoplastic cells and stromal fibroblastic cells that undergo
activation of EMT induced TFs due to growth factors pro-
duced by the tumor [17].
There are several possible explanations for observed
data. One of the possibilities is the intratumoral hetero-
geneity and CTCs, believed to be released only from the
tumor edge, may not comprise the heterogeneous tumor
population. Examination of the tissue sections from the
bulk of tumor mass could miss the small areas of EMT
TFs overexpression, as well. Thus, we canot exclude that
relationship between CTCs in peripheral blood and
tissue expression of EMT TFs is not dose dependent.
Another explanation could be related to limited accuracy
of immunohistochemistry to quantitate EMT TFs ex-
pression compared to more precise methods such as
qRT-PCR. The absence of correlation could be also due
to post translational modifications that causes that
mRNA and protein levels do not always correlated. Pres-
ence of CTCs in peripheral blood is a dynamic state, and
it is possible, that this is not mirrored by expression of
EMT TFs in primary tumor tissue. Different detection
methods are capable of detecting different subpopula-
tions of CTCs with different clinical and biological value
[5]. All data regarding CTCs, should be therefore inter-
preted within the context of the detection method used.
In our study we detected CTCs by qRT-PCR methods
based on expression of KRT19 and EMT-TFs respect-
ively with pre-enrichment step utilizing CD45 negative
selection, unfortunately, CD45 depleted cells do not ne-
cessarily contain only CTCs. Therefore we defined CTCs
positivity based on the cut-off value that was established
as the highest expression of corresponding gene in
population of healthy donors. However, we cannot ex-
clude correlation between expression of EMT-TF in pri-
mary tumor and CTCs detected by different detection
method. Finally, limited sample size could affect study
results; however, we did not observe nor the trend for
correlation between CTCs and expression of EMT TFs
in primary tumor. Our data suggest, that EMT TFs ex-
pression in unselected tumor tissue did not play a major
role in CTCs release, and it is possible, that other factors
or signaling pathways are more closely associated with
CTCs. Recently, it was identified tumor gene expression
profile able to reveal patients with detectable CTCs in
primary breast cancer patients [27]. In that study, EMT-
TFs TWIST and SLUG were not part of CTC-predictive
profile, but definition of CTCs was different compared
to our study [27].
Conclusion
In conclusion, in this prospective translational study,
we showed for the first time a lack of association
between CTCs in peripheral blood and expression of
EMT-inducing transcription factors, TWIST1 and
SLUG, in primary breast tumor tissue. These results
suggest, that expression of EMT proteins in unse-
lected tumor tissue is not surrogate marker of CTCs
with either mesenchymal or epithelial features. Future
studies will be need to identify expression of proteins
in tumor tissue associated with presence of CTCs in
the peripheral blood. These proteins could represent
surrogate markers for biologically more aggressive dis-
ease and could represent potentially new therapeutic
targets to inhibit metastatic process.
Table 5 Correlation between CTCs and expression of TWIST1
and SLUG in primary tumor
SLUGa TWIST1a
Cancer Stroma Cancer Stroma
CTC Epithelialb
Spearman rho’ 0.03 0.13 −0.07 0.02
p-valuec 0.79 0.21 0.48 0.82
CTC EMTb
Spearman rho’ 0.00 −0.09 −0.01 0.02
p-valuec 0.97 0.41 0.89 0.88
CTC Anyb
Spearman rho’ 0.04 0.02 −0.06 0.06
p-valuec 0.73 0.87 0.55 0.59
aProtein expression evaluated semi quantitatively by immunohistochemistry
bCTC detected by quantitative RT-PCR
cSpearman’s correlation test
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